Philip E. LeBoit
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Philip E. LeBoit has a total of 41 co-authors. Here are the top co-authors by number of shared publications:
Yann Charli-Joseph
Cutaneous Hematopathology Clinic, National Institute of Health Sciences and Nutrition, Salvador Zubirán, Mexico City, Mexico †Research Unit of Dermatopathology, Department of Dermatology, Medical University of Graz, Graz, Austria ‡Departments of Pathology and Dermatology, University of California, San Francisco §UCSF Helen A. Diller Family Comprehensive Cancer Center, San Francisco, CA
3 shared publicationsAndrea Saggini
Pathology, University of California San Francisco, San Francisco, California; Dermatology, University of California San Francisco, San Francisco, California
2 shared publicationsJingly Weier
Pathology, University of California San Francisco, San Francisco, California
2 shared publicationsLorenzo Cerroni
Cutaneous Hematopathology Clinic, National Institute of Health Sciences and Nutrition, Salvador Zubirán, Mexico City, Mexico
2 shared publicationsSonia Mirza
Pathology, University of California San Francisco, San Francisco, California
2 shared publicationsSwapna Vemula
Pathology, University of California San Francisco, San Francisco, California
2 shared publications
Latest Publications
- 10 September 2024
Spitz melanoma.
It has long been recognized that the histopathologic differential diagnosis between Spitz nevus and melanoma is sometimes extraordinarily difficult. Both can be composed of large oval to spindled melanocytes with abundant cytoplasm and large nuclei. Genomic studies over the last decade have clarified that Spitz tumors have diverse genetic initiating events, and that for each of these, there are benign, intermediate grade, and malignant lesions. Another discovery is that some melanomas can morphologically resemble Spitz tumors but have conventional initiating mutations (e.g., BRAF, NRAS). The current WHO definition of Spitz tumors restricts the spectrum to neoplasms with an activating mutation affecting the MAP kinase pathway, mostly fusions involving kinase genes. Whether splitting off Spitz tumors from other neoplasms that are only morphologically spitzoid will stand the test of time is uncertain, but for now, it does bring order to what has been a complex area. The recognition of Spitz melanoma will enable classification, follow-up, and the delineation of rational treatment guidelines for this important group of tumors, most of which are in young people. I have reviewed the logic of the WHO definition of Spitz tumors, the spectrum of tumors produced by initiating mutations, problems with the definition of Spitz melanoma, and have provided an example of this rare entity in the context of related tumors.
- 10 September 2024
Spitz melanoma.
It has long been recognized that the histopathologic differential diagnosis between Spitz nevus and melanoma is sometimes extraordinarily difficult. Both can be composed of large oval to spindled melanocytes with abundant cytoplasm and large nuclei. Genomic studies over the last decade have clarified that Spitz tumors have diverse genetic initiating events, and that for each of these, there are benign, intermediate grade, and malignant lesions. Another discovery is that some melanomas can morphologically resemble Spitz tumors but have conventional initiating mutations (e.g., BRAF, NRAS). The current WHO definition of Spitz tumors restricts the spectrum to neoplasms with an activating mutation affecting the MAP kinase pathway, mostly fusions involving kinase genes. Whether splitting off Spitz tumors from other neoplasms that are only morphologically spitzoid will stand the test of time is uncertain, but for now, it does bring order to what has been a complex area. The recognition of Spitz melanoma will enable classification, follow-up, and the delineation of rational treatment guidelines for this important group of tumors, most of which are in young people. I have reviewed the logic of the WHO definition of Spitz tumors, the spectrum of tumors produced by initiating mutations, problems with the definition of Spitz melanoma, and have provided an example of this rare entity in the context of related tumors.
- Open Access
- 17 January 2022
- Published by Wolters Kluwer Health in American Journal of Surgical Pathology
- Vol. 46 (6) , 729-741
HPV51-associated Leiomyosarcoma
Inactivating mutations in tumor suppressor genes TP53 and RB1 are considered central drivers in leiomyosarcomas (LMSs). In high-risk human papillomavirus (HPV)-related tumors, a similar functional outcome is achieved through oncoproteins E6 and E7, which inactivate the p53 and RB1 proteins, respectively. Here, we hypothesized that HPV infection could provide an alternative mechanism for tumorigenesis in a subset of TP53/RB1-wildtype LMS. We evaluated tumor samples from 2585 consecutive unique patients carrying a diagnosis of gynecologic or soft tissue LMS. Tumor DNA and available RNA were analyzed by hybrid-capture-based next-generation sequencing/comprehensive genomic profiling of 406 genes and transcripts (FoundationOneHeme). Of the initial 2585 cases, we excluded 16 based on the presence of molecular alterations that are considered defining for sarcomas other than LMS. In the remaining 2569 cases, we searched for LMS that were TP53/RB1-wildtype (n=486 of 2569; 18.9%). We also searched LMS tumors for HPV sequences that we then classified into genotypes by de novo assembly of nonhuman sequencing reads followed by alignment to the RefSeq database. Among TP53/RB1-wildtype LMS, we identified 18 unique cases harboring HPV sequences. Surprisingly, most (n=11) were HPV51-positive, and these 11 represented all HPV51-positive tumors in our entire LMS database (n=11 of 2569; 0.4%). The absence of genomic alterations in TP53 or RB1 in HPV51-positive LMS represented a marked difference from HPV51-negative LMS (n=2558; 0% vs. 72% [PP=0.0002]). In addition, compared with HPV51-negative LMS, HPV51-positive LMS were significantly enriched for genomic alterations in ATRX (55% vs. 24%, P=0.027) and TSC1 (18% vs. 0.6%, P=0.0047). All HPV51-positive LMS were in women; median age was 54 years at surgery (range: 23 to 74 y). All known primary sites were from the gynecologic tract or adjacent anogenital area, including 5 cases of vaginal primary site. Histology was heterogeneous, with evaluable cases showing predominant epithelioid (n=5) and spindle (n=5) morphology. In situ hybridization confirmed the presence of high-risk HPV E6/E7 mRNA in tumor cells in three of three evaluable cases harboring HPV51 genomic sequences. Overall, in our pan-LMS analysis, HPV reads were identified in a subset of TP53/RB1-wildtype LMS. For all HPV51-associated LMS, the striking absence of any detectable TP53 or RB1 mutations and predilection for the female lower reproductive tract supports our hypothesis that high-risk HPV can be an alternative tumorigenic mechanism in this distinct class of LMS.
- 17 January 2022
- Published by Wolters Kluwer Health in American Journal of Surgical Pathology
- Vol. 46 (6) , 729-741
Open AccessHPV51-associated Leiomyosarcoma
Inactivating mutations in tumor suppressor genes TP53 and RB1 are considered central drivers in leiomyosarcomas (LMSs). In high-risk human papillomavirus (HPV)-related tumors, a similar functional outcome is achieved through oncoproteins E6 and E7, which inactivate the p53 and RB1 proteins, respectively. Here, we hypothesized that HPV infection could provide an alternative mechanism for tumorigenesis in a subset of TP53/RB1-wildtype LMS. We evaluated tumor samples from 2585 consecutive unique patients carrying a diagnosis of gynecologic or soft tissue LMS. Tumor DNA and available RNA were analyzed by hybrid-capture-based next-generation sequencing/comprehensive genomic profiling of 406 genes and transcripts (FoundationOneHeme). Of the initial 2585 cases, we excluded 16 based on the presence of molecular alterations that are considered defining for sarcomas other than LMS. In the remaining 2569 cases, we searched for LMS that were TP53/RB1-wildtype (n=486 of 2569; 18.9%). We also searched LMS tumors for HPV sequences that we then classified into genotypes by de novo assembly of nonhuman sequencing reads followed by alignment to the RefSeq database. Among TP53/RB1-wildtype LMS, we identified 18 unique cases harboring HPV sequences. Surprisingly, most (n=11) were HPV51-positive, and these 11 represented all HPV51-positive tumors in our entire LMS database (n=11 of 2569; 0.4%). The absence of genomic alterations in TP53 or RB1 in HPV51-positive LMS represented a marked difference from HPV51-negative LMS (n=2558; 0% vs. 72% [PP=0.0002]). In addition, compared with HPV51-negative LMS, HPV51-positive LMS were significantly enriched for genomic alterations in ATRX (55% vs. 24%, P=0.027) and TSC1 (18% vs. 0.6%, P=0.0047). All HPV51-positive LMS were in women; median age was 54 years at surgery (range: 23 to 74 y). All known primary sites were from the gynecologic tract or adjacent anogenital area, including 5 cases of vaginal primary site. Histology was heterogeneous, with evaluable cases showing predominant epithelioid (n=5) and spindle (n=5) morphology. In situ hybridization confirmed the presence of high-risk HPV E6/E7 mRNA in tumor cells in three of three evaluable cases harboring HPV51 genomic sequences. Overall, in our pan-LMS analysis, HPV reads were identified in a subset of TP53/RB1-wildtype LMS. For all HPV51-associated LMS, the striking absence of any detectable TP53 or RB1 mutations and predilection for the female lower reproductive tract supports our hypothesis that high-risk HPV can be an alternative tumorigenic mechanism in this distinct class of LMS.
- 21 April 2021
- Published by Wolters Kluwer Health in The American Journal of Dermatopathology
- Vol. 43 (11) , 788-793
Desmoplastic Trichoepithelioma With Pseudocarcinomatous Hyperplasia: A Folliculosebaceous Neoplasm in Young Persons
Pseudocarcinomatous desmoplastic trichoepithelioma (PDTE) features verrucous squamous epidermal hyperplasia with a jagged undersurface overlying cords of follicular germinative cells in a fibrotic stroma. To date, only 5 cases have been reported. We identified 7 new PDTEs from 2 institutions and reviewed their clinical manifestations and immunohistochemical profile. The median age was 14 years (range 8–34 years). New findings included vacuolization of the basal layer of the pseudocarcinomatous surface epithelium, and the frequent presence of singly distributed sebocytes within the cords of basaloid cells. The immunohistochemical profile resembles desmoplastic trichoepithelioma, with expression of TDAG51, CK15, and Ber-Ep4. Colonizing CK20+ Merkel cells were present in all cases. PDTE needs to be differentiated from malignant neoplasms such as squamous cell carcinoma, morphoeic basal cell carcinoma, and microcystic adnexal carcinoma. Recognizing the features of this sclerosing folliculosebaceous neoplasm facilitates accurate diagnosis and avoids overtreatment.
- 21 April 2021
- Published by Wolters Kluwer Health in The American Journal of Dermatopathology
- Vol. 43 (11) , 788-793
Desmoplastic Trichoepithelioma With Pseudocarcinomatous Hyperplasia: A Folliculosebaceous Neoplasm in Young Persons
Pseudocarcinomatous desmoplastic trichoepithelioma (PDTE) features verrucous squamous epidermal hyperplasia with a jagged undersurface overlying cords of follicular germinative cells in a fibrotic stroma. To date, only 5 cases have been reported. We identified 7 new PDTEs from 2 institutions and reviewed their clinical manifestations and immunohistochemical profile. The median age was 14 years (range 8–34 years). New findings included vacuolization of the basal layer of the pseudocarcinomatous surface epithelium, and the frequent presence of singly distributed sebocytes within the cords of basaloid cells. The immunohistochemical profile resembles desmoplastic trichoepithelioma, with expression of TDAG51, CK15, and Ber-Ep4. Colonizing CK20+ Merkel cells were present in all cases. PDTE needs to be differentiated from malignant neoplasms such as squamous cell carcinoma, morphoeic basal cell carcinoma, and microcystic adnexal carcinoma. Recognizing the features of this sclerosing folliculosebaceous neoplasm facilitates accurate diagnosis and avoids overtreatment.
- 1 July 2019
- Published by American Medical Association (AMA) in JAMA Dermatology
- Vol. 155 (7) , 775-776
The Morphology of Tumor Progression in Melanoma In Situ
Pathology reports frame conversations between clinicians and patients. In the case of dermatopathology reports, in the best of circumstances, the histopathologi
- 1 July 2019
- Published by American Medical Association (AMA) in JAMA Dermatology
- Vol. 155 (7) , 775-776
The Morphology of Tumor Progression in Melanoma In Situ
Pathology reports frame conversations between clinicians and patients. In the case of dermatopathology reports, in the best of circumstances, the histopathologi
- 12 October 2018
- Published by Wiley in Journal of Cutaneous Pathology
- Vol. 46 (1) , 90-92
Is CD1a useful for leishmaniasis diagnosis in the New World?
- 12 October 2018
- Published by Wiley in Journal of Cutaneous Pathology
- Vol. 46 (1) , 90-92
Is CD1a useful for leishmaniasis diagnosis in the New World?
- 1 June 2015
- Published by Wolters Kluwer Health in American Journal of Surgical Pathology
- Vol. 39 (6) , 737-743
Cutaneous Spindle-Cell B-Cell Lymphomas
Cutaneous lymphomas of both B cells and less commonly T cells can exceptionally exhibit spindle-cell morphology. Less than 30 spindle-cell B-cell lymphomas of the skin have been described, mostly before the adoption of detailed immunohistochemistry, and thus initially interpreted as variants of diffuse large B-cell lymphoma (DLBCL). Furthermore, some authors suggest that cutaneous spindle-cell B-cell lymphomas (cSCBCLs) may behave more aggressively than their conventional morphologic counterparts and may thus merit more aggressive treatment. Herein we describe the largest case series of cSCBCL analyzed to date to characterize their clinicopathologic and immunohistochemical features and clarify their subtype according to the current WHO/EORTC classification scheme. Twenty-four cSCBCLs arose in 18 male and 6 female individuals with a mean age of 55 years, mostly on the head (12/24), trunk (8/24), and lower extremities (4/24). Histopathologic features were similar for all cases. Neoplasms involved the entire dermis and focally the subcutis. The neoplastic infiltrates comprised a mixture of medium-sized, visually prominent spindled cells (15%; up to 85% of the infiltrate) arranged in a fascicular pattern around nodular aggregates and admixed in a random manner between centrocyte/centroblast-like cells within these nodular collections. Immunohistochemical support for a follicular center cell origin was present in 22/24 cases, 1 was consistent with DLBCL-leg type and 1 defied precise classification, best fitting with intermediate-grade DLBCL-other. Our findings reinforce the concept that most cSCBCLs are variants of low-grade B-cell lymphomas of follicle center cell origin and not intermediate-grade variants of DLBCL.
- 1 June 2015
- Published by Wolters Kluwer Health in American Journal of Surgical Pathology
- Vol. 39 (6) , 737-743
Cutaneous Spindle-Cell B-Cell Lymphomas
Cutaneous lymphomas of both B cells and less commonly T cells can exceptionally exhibit spindle-cell morphology. Less than 30 spindle-cell B-cell lymphomas of the skin have been described, mostly before the adoption of detailed immunohistochemistry, and thus initially interpreted as variants of diffuse large B-cell lymphoma (DLBCL). Furthermore, some authors suggest that cutaneous spindle-cell B-cell lymphomas (cSCBCLs) may behave more aggressively than their conventional morphologic counterparts and may thus merit more aggressive treatment. Herein we describe the largest case series of cSCBCL analyzed to date to characterize their clinicopathologic and immunohistochemical features and clarify their subtype according to the current WHO/EORTC classification scheme. Twenty-four cSCBCLs arose in 18 male and 6 female individuals with a mean age of 55 years, mostly on the head (12/24), trunk (8/24), and lower extremities (4/24). Histopathologic features were similar for all cases. Neoplasms involved the entire dermis and focally the subcutis. The neoplastic infiltrates comprised a mixture of medium-sized, visually prominent spindled cells (15%; up to 85% of the infiltrate) arranged in a fascicular pattern around nodular aggregates and admixed in a random manner between centrocyte/centroblast-like cells within these nodular collections. Immunohistochemical support for a follicular center cell origin was present in 22/24 cases, 1 was consistent with DLBCL-leg type and 1 defied precise classification, best fitting with intermediate-grade DLBCL-other. Our findings reinforce the concept that most cSCBCLs are variants of low-grade B-cell lymphomas of follicle center cell origin and not intermediate-grade variants of DLBCL.
- 1 December 2014
- Published by Elsevier in Journal of the American Academy of Dermatology
- Vol. 71 (6) , 1127-1136
Primary cutaneous perivascular epithelioid cell tumor: A clinicopathological and molecular reappraisal
- 1 December 2014
- Published by Elsevier in Journal of the American Academy of Dermatology
- Vol. 71 (6) , 1127-1136
Primary cutaneous perivascular epithelioid cell tumor: A clinicopathological and molecular reappraisal
- 1 August 2014
- Published by Elsevier in Journal of the American Academy of Dermatology
- Vol. 71 (2) , 256-263
DNA copy number changes in tumors within the spectrum of cellular, atypical, and metastasizing fibrous histiocytoma
- 1 August 2014
- Published by Elsevier in Journal of the American Academy of Dermatology
- Vol. 71 (2) , 256-263
DNA copy number changes in tumors within the spectrum of cellular, atypical, and metastasizing fibrous histiocytoma
- 1 March 2014
- Published by Wolters Kluwer Health in The American Journal of Dermatopathology
- Vol. 36 (3) , 229-237
Angiomatous Kaposi Sarcoma
We describe 14 cases of angiomatous Kaposi sarcoma (KS), a distinct histological variant of KS first mentioned by Gottlieb and Ackerman in 1988 that can easily be mistaken for a hemangioma. Intriguingly, this variant of KS has not attracted much attention and has not been studied in detail. Immunohistochemistry showed prominent staining of podoplanin (D2-40) of the neoplastic vasculature but not the preexisting vessels, suggesting lymphatic differentiation, despite the erythrocyte-filled round lumens. To test whether D2-40 staining of round vessels with erythrocytes was distinctive, we stained sinusoidal hemangiomas and cellular angiolipomas, both of which have these structures. In contrast to angiomatous KS, the vessels in both entities were podoplanin (D2-40) negative. The finding of round erythrocyte-filled vessels with podoplanin (D2-40) positivity may be distinctive for this form of KS.
- 1 March 2014
- Published by Wolters Kluwer Health in The American Journal of Dermatopathology
- Vol. 36 (3) , 229-237
Angiomatous Kaposi Sarcoma
We describe 14 cases of angiomatous Kaposi sarcoma (KS), a distinct histological variant of KS first mentioned by Gottlieb and Ackerman in 1988 that can easily be mistaken for a hemangioma. Intriguingly, this variant of KS has not attracted much attention and has not been studied in detail. Immunohistochemistry showed prominent staining of podoplanin (D2-40) of the neoplastic vasculature but not the preexisting vessels, suggesting lymphatic differentiation, despite the erythrocyte-filled round lumens. To test whether D2-40 staining of round vessels with erythrocytes was distinctive, we stained sinusoidal hemangiomas and cellular angiolipomas, both of which have these structures. In contrast to angiomatous KS, the vessels in both entities were podoplanin (D2-40) negative. The finding of round erythrocyte-filled vessels with podoplanin (D2-40) positivity may be distinctive for this form of KS.
- 1 January 2014
- Published by Wolters Kluwer Health in Pathology Case Reviews
- Vol. 19 (4) , 185-186
Cutaneous Lymphoproliferative Disease
- 1 January 2014
- Published by Wolters Kluwer Health in Pathology Case Reviews
- Vol. 19 (4) , 185-186
Cutaneous Lymphoproliferative Disease